ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$1.64
-0.02 (-0.91%)
▼
5d:
-4.09%
30d:
+40.17%
90d:
+42.61%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 14, 2026
30d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ENTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ENTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $1.64, which is considered slightly high relative to its 30-day fair value range of $1.23 to $1.68.
Technical Outlook: Technically, ENTX is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.00 (+448.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENTX is in a downtrend. The price is approaching resistance at $1.37. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.00 (+448.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.23 -
$1.68
Company Quality Score
56/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: Trading 448.8% below Wall St target ($9.00)
Trading Range Analysis
30-Day Trading Range
$1.23 -
$1.68
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.37
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.88
Wall Street Target
$9.00
(+448.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 14, 2026 9:01 AM ET
Data refreshes hourly during market hours. Next update: 10:01 AM
Data refreshes hourly during market hours. Next update: 10:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Sean Ellis
BUY
18000 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
